<DOC>
	<DOCNO>NCT00716625</DOCNO>
	<brief_summary>The objective surveillance collect information 1 ) adverse drug reaction expect LPD ( unknown adverse drug reaction ) , 2 ) incidence adverse drug reaction surveillance , 3 ) factor consider affect safety and/or efficacy drug .</brief_summary>
	<brief_title>Special Investigation For Renal Cell Carcinoma ( RCC ) Of Sunitinib Malate ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes first sunitinib malate ( Sutent ) register .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients need administer sunitinib malate ( Sutent ) order enrol surveillance . Patients administer sunitinib malate ( Sutent ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>